LYRA
Lyra Therapeutics Inc
NASDAQ: LYRA · HEALTHCARE · BIOTECHNOLOGY
$0.75
-5.71% today
Updated 2026-06-03
Market cap
$870050.00
P/E ratio
—
P/S ratio
1.45x
EPS (TTM)
$-22.90
Dividend yield
—
52W range
$0 – $34
Volume
0.0M
WallStSmart proprietary scores
24
out of 100
Grade: F
Strong Sell
Investment rating
5.3
Growth
C+6.0
Quality
B2.5
Profitability
F6.0
Valuation
B2/9
Piotroski F-Score
Weak
-10.9
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$16.00
+2033.33%
12-Month target
—
—
Intrinsic (DCF)
$1.81
Margin of safety
+24.31%
Price chart
Stock snapshot
Strengths
+ 24.31% below intrinsic value
+ Debt/equity -7.25x — low leverage
Risks
- Piotroski 2/9 — weak financial health
- Altman Z -10.86 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-7.36M
- Revenue declining -87.20% QoQ
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|
| Revenue | $285000.00 | $1.36M | $1.56M | $1.53M | $600000.00 |
| Net income | $-42.41M | $-55.28M | $-62.68M | $-93.44M | $-5.98M |
| EPS | — | — | — | — | $-22.90 |
| Free cash flow | $-29.20M | $-43.55M | $-64.35M | $-72.35M | $-7.36M |
| Profit margin | -14,880.70% | -4,055.61% | -4,023.11% | -6,090.94% | — |
Peer comparison
Smart narrative
Lyra Therapeutics Inc trades at $0.75. Our Smart Value Score of 24/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of -10.86, it sits in the distress. TTM revenue stands at $600000.00. Our DCF model estimates intrinsic value at $1.81.
Frequently asked questions
What is Lyra Therapeutics Inc's stock price?
Lyra Therapeutics Inc (LYRA) trades at $0.75, on a P/S of 1.5x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Lyra Therapeutics Inc overvalued?
Lyra Therapeutics Inc carries a Smart Value Score of 24/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read. Our DCF puts intrinsic value at $1.81 versus the $0.75 price, a 24.3% margin of safety on a cash flow basis.
What is the price target of Lyra Therapeutics Inc (LYRA)?
The 12-month analyst consensus target is $16.00, about 2033.3% above the current $0.75. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the intrinsic value of Lyra Therapeutics Inc (LYRA)?
Our DCF model estimates intrinsic value at $1.81, a +24.3% margin of safety versus today's $0.75. Intrinsic value is what the projected cash flows are worth today. A positive reading means the price sits below that estimate, leaving a cushion if growth holds.
What is Lyra Therapeutics Inc's revenue?
Lyra Therapeutics Inc's trailing twelve-month revenue is $600000.00. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Lyra Therapeutics Inc's Altman Z-Score is -10.86, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio1.45x
ROE-404.50%
Beta0.06
50D MA$1.82
200D MA$5.95
Shares out0.00B
Float0.00B
Short ratio—
Avg volume0.0M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—